Non-conditional logistic analysis further revealed that low FST expressions correlated with risks of HER-2 positive BC (OR = 0.38, 95% CI: 0.16–0.88), TNBC (OR = 0.71, 95% CI: 0.35–1.43), Mucinous BC (OR = 0.17, 95% CI: 0.06–0.48) tumors, and dead status (OR = 0.50, 95% CI: 0.27–0.93) (Additional file 1: Table S1). The gene discussed is ERBB2; the disease is breast cancer.